CK Life Sciences (HKG:0775) swung to an attributable loss of HK$126.6 million in 2024 from a profit of HK$17.3 million in 2023, according to a Tuesday filing with the Hong Kong bourse.
The biotechnology company swung to a loss per share of HK$0.0132 from earnings per share of HK$0.0018 in the previous year.
Revenue increased to HK$5.52 billion compared with HK$5.32 billion in the previous year.
Shares slid 3% during Wednesday's morning trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.